Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.

Breast cancer research and treatment - 1 Jul 2009

Kontorovich Tair, Cohen Yoram, Nir Uri, Friedman Eitan

Abstract excerpt

BRCA1/BRCA2 germline mutations substantially increase breast and ovarian cancer risk, yet penetrance is incomplete. We hypothesized that germline epigenetic gene silencing may affect mutant BRCA1/2 penetrance. To test this notion, we determined the methylation status, using methylation-specific quantitative PCR of the promoter in putative modifier genes: BRCA1, BRCA2, ATM, ATR and P53 in Jewish BRCA1/BRCA2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Cell Cycle Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Israel

Share to Ovarian Neoplasms

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 18642075
DOI: 10.1007/s10549-008-0121-3

Genes

BRCA1
BRCA2
ATM
ATR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.PMID 18642075Read ↗

Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.Semantic proximity Read ↗

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.Semantic proximity Read ↗

BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women.Semantic proximity Read ↗

Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.Semantic proximity Read ↗

FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations.Semantic proximity Read ↗

Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.Semantic proximity Read ↗

Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women.Semantic proximity Read ↗

Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.Semantic proximity Read ↗

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

ATM haplotypes and breast cancer risk in Jewish high-risk women.Semantic proximity Read ↗

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.